Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

This study has been terminated.
Information provided by:
Abbott Identifier:
First received: October 16, 2003
Last updated: August 2, 2006
Last verified: August 2006
The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs. Depakote monotherapy and olanzapine monotherapy in stable subjects during the maintenance phase of bipolar illness.

Condition Intervention Phase
Bipolar Disorder
Drug: Divalproex Sodium (Delayed-Release Tablets)
Drug: Divalproex Sodium (Extended-Release Tablets)
Drug: Olanzapine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • CGI-s
  • CGI-i
  • MRS
  • DSS
  • SADS-C

Estimated Enrollment: 180
Study Start Date: July 2003

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • DSM-IV-TR primary diagnosis of Bipolar I Disorder as confirmed by the SCID
  • Outpatient receiving treatment with a combination of Depakote plus olanzapine for their bipolar illness and considered clinically stable (e.g., no more than minimal symptoms, no psychiatric hospitalizations, no increase in intensity of clinical interventions) for the preceding 4 months
  • Identified at Screening a most bothersome side effect listed in the UKU which makes switching to monotherapy desirable
  • MRS total score < 12 on two consecutive ratings, separated by at least 5 days (Screening and Day 1)
  • DSS score < 13 on two consecutive ratings, separated by at least five days (Screening and Day 1)
  • CGI-S score < 3 on two consecutive ratings, separated by at least five days (Screening and Day 1)
  • Serum valproate level > 45 mcg/mL, and a maximum allowable dose of Depakote of 3000 mg/day at Screening
  • Olanzapine dose between 5 and 20 mg/day at Screening

Exclusion Criteria:

  • History of schizophrenia or schizoaffective disorder
  • Axis I (e.g., anxiety disorder) or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results
  • Has taken antipsychotics, mood stabilizers, or anticonvulsants (unless specifically for seizure control) other than Depakote or olanzapine in the four months prior to randomization. Other psychotropics (e.g., antidepressants, anxiolytics) with the exception of stimulants, that have been used routinely to maintain stability in the preceding four months may be continued, but not increased or decreased
  • Has first manic episode after age 60
  • Has ever taken clozapine
  • Has received depot neuroleptic medication within six months of randomization
  • Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine or amphetamines
  • History of active alcohol or substance abuse/dependence within 90 days prior to Screening
  • Known history of non-response to either Depakote or olanzapine monotherapy for the treatment of bipolar disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00071253

United States, California
Behavioral and Medical Research, LLC
Anaheim, California, United States, 92805
Synergy Clinical Research
Chula Vista, California, United States, 91910
United States, Florida
Clinical Trial Management
Fort Meyers, Florida, United States, 33907
Segal Institute for Clinical Research
North Miami, Florida, United States, 33161
United States, Illinois
Rush Presbyterian - St. Luke's
Chicago, Illinois, United States, 60612
United States, Kentucky
University of Louisville Outpatient Psychiatry
Louisville, Kentucky, United States, 40202
United States, Mississippi
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, Nebraska
Creighton University Department of Psychiatry
Omaha, Nebraska, United States, 68131
United States, Nevada
Lake Mead Hospital
North Las Vegas, Nevada, United States, 89030
United States, New York
NYU School of Medicine
New York City, New York, United States, 10016
United States, Ohio
University Hospital of Cleveland
Cleveland, Ohio, United States, 44106
R. Ranjan, MD & Associates, Inc.
Lyndhurst, Ohio, United States, 44124
United States, Oklahoma
IPS Research
Oklahoma City, Oklahoma, United States, 73103
United States, Texas
UTMB Dept. of Psychiatry
Galveston, Texas, United States, 77555-0197
United States, Wisconsin
Zablocki VAMC
Milwaukee, Wisconsin, United States, 53295
Sponsors and Collaborators
Study Director: Global Medical Information Abbott
  More Information Identifier: NCT00071253     History of Changes
Other Study ID Numbers: M02-551
Study First Received: October 16, 2003
Last Updated: August 2, 2006

Keywords provided by Abbott:
Bipolar Disorder - Mania

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Valproic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Antipsychotic Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Serotonin Agents processed this record on April 27, 2017